Kyverna Therapeutics has appointed Nadia Dac as Chief Commercial Officer to spearhead the commercial launch of miv-cel, a promising CAR T-cell therapy for autoimmune diseases like stiff person syndrome. Dac brings over 30 years of experience in biopharma commercial leadership, having led successful product launches in neurology and rare diseases. Her role is crucial as Kyverna prepares to transition to a commercial-stage company and expand miv-cel’s use into other neuroimmunology conditions. The company also granted her stock options as part of her employment inducement.
California Resources Corporation has completed the first CO₂ injection at Carbon TerraVault I, California's first operational carbon capture and storage (CCS) project located in Kern County. This milestone marks a significant step toward California's...
REalloys Inc. has committed $20.6 million to upgrade the Saskatchewan Research Council's rare earth processing facility, increasing production capacity for critical rare earth metals like Neodymium-Praseodymium, Dysprosium, and Terbium. These upgrade...
Baker Hughes has extended and expanded its contract with Petrobras to provide integrated well construction solutions in Brazil's Santos Basin. The company will deploy advanced technologies like the AutoTrak rotary steerable system and Dynamus drill b...
Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending its cash runway into 2028. This funding supports the advancement of multiple clinical trials for its CAR...
Rocket Lab's stock surged following strong Q1 2026 results, with revenue up 63.5% year-over-year to $200.3 million and a record backlog of $2.2 billion. The company also secured a $90 million contract from the U.S. Space Force to design and manufactu...
